Does Rallies show Form 4 insider transactions for ALZN?

Yes. Rallies tracks ALZN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ALZN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ALZN. It does not provide personalized investment advice.

ALZN (Alzamend Neuro, Inc. Common Stock) Stock Analysis - Insider Trades

Alzamend Neuro, Inc. Common Stock (ALZN) is a publicly traded Healthcare sector company. As of May 21, 2026, ALZN trades at $1.24 with a market cap of $3.88M and a P/E ratio of -0.09. ALZN moved +23.76% today. Year to date, ALZN is -41.46%; over the trailing twelve months it is -65.91%. Its 52-week range spans $0.84 to $17.10. Analyst consensus is buy with an average price target of $25.00. Rallies surfaces ALZN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ALZN stock inside the company?

Recent ALZN insider activity includes AULT MILTON C III bought 108.39K, AULT MILTON C III sold 1.85K, Horne William B. sold 3.33K, McGrath Lynne Fahey sold 30, and AULT MILTON C III sold 20.40K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ALZN Key Metrics

Key financial metrics for ALZN
Metric	Value
Price	$1.24
Market Cap	$3.88M
P/E Ratio	-0.09
EPS	$-11.32
Dividend Yield	0.00%
52-Week High	$17.10
52-Week Low	$0.84
Volume	167.39K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$4.50M
Gross Margin	0.00%

Recent ALZN Insider Trades

AULT MILTON C III bought 108.39K (~$108.90K) on Apr 14, 2026.
AULT MILTON C III sold 1.85K (~$3.83K) on Dec 23, 2025.
Horne William B. sold 3.33K (~$7.06K) on Dec 19, 2025.
McGrath Lynne Fahey sold 30 (~$68.7) on Oct 23, 2025.
AULT MILTON C III sold 20.40K (~$47.39K) on Oct 9, 2025.

Latest ALZN News

Alzamend’s AL001 Reduces Myo-Inositol in 17 of 18 Regions, Spares Glutamate — Apr 7, 2026
Alzamend Neuro's AL001 Shows 7.8% Higher Brain Lithium Delivery, Faster 6.7h Uptake — Mar 26, 2026
Alzamend Neuro Launches Phase II Crossover Trial of AL001 vs Lithium Carbonate — Mar 16, 2026

ALZN Analyst Consensus

1 analysts cover ALZN: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $25.00.

Common questions about ALZN

Who is trading ALZN stock inside the company?: Recent ALZN insider activity includes AULT MILTON C III bought 108.39K, AULT MILTON C III sold 1.85K, Horne William B. sold 3.33K, McGrath Lynne Fahey sold 30, and AULT MILTON C III sold 20.40K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ALZN?: Yes. Rallies tracks ALZN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ALZN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ALZN. It does not provide personalized investment advice.